Ginsenosides combined with dexamethasone in preventing and treating postembolization syndrome following transcatheter arterial chemoembolization: A randomized, controlled and double-blinded prospective trial

2005 ◽  
Vol 3 (2) ◽  
pp. 99-102 ◽  
Author(s):  
Ying-Lu Feng
Keyword(s):  
Transcatheter Arterial Chemoembolization ◽  
Prospective Trial ◽  
Randomized Controlled ◽  
Double Blinded ◽  
Postembolization Syndrome ◽  
Arterial Chemoembolization

scholarly journals Systematic Review and Meta-analysis of Endostar Combined With Transcatheter Arterial Chemoembolization (TACE) Versus TACE Alone for Hepatocellular Carcinoma

2017 ◽  
Vol 22 (4) ◽  
pp. 883-891 ◽  
Author(s):  
Ya-Qing Zhang ◽  
Fei Zhao ◽  
Lei Song ◽  
Hong-Yun Gan ◽  
Xiao-Feng Xie
Keyword(s):  
Hepatocellular Carcinoma ◽  
Systematic Review ◽  
Randomized Trials ◽  
Overall Response Rate ◽  
Transcatheter Arterial Chemoembolization ◽  
Response Rate ◽  
Meta Analysis ◽  
Randomized Controlled ◽  
Negative Conversion ◽  
Arterial Chemoembolization

Many studies have investigated the efficacy of Endostar combined with transcatheter arterial chemoembolization (TACE) versus TACE alone for hepatocellular carcinoma (HCC). A systematic review was conducted to evaluate the efficacy of Endostar. PubMed, Embase, and other databases were searched, and meta-analysis was performed using RevMan 5.3 software. Nine studies, all of which were clinical randomized controlled trials, involving 411 participants were included. The overall response rate, disease control rate and α-fetoprotein negative conversion ratio, and the 6- and 12-month survival rate of HCC patients treated with combined Endostar and TACE were higher than those treated with TACE alone ( P < .01). Furthermore, the incidence of tumor progression was low after Endostar treatment ( P = .005). The incidence of adverse effects (leukocytopenia, liver function damage, and vomiting) was similar in Endostar with TACE and in TACE alone ( P > .05). However, large studies and more randomized trials are necessary to determine the effects of Endostar on HCC.

scholarly journals Comparison of Radiofrequency Ablation with or without Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma: A Meta-Analysis of Randomized Controlled Trials

2021 ◽  
Author(s):  
Xinxin Wang ◽  
Yang Che ◽  
Shiyong Chen ◽  
Biao Wu ◽  
Yu He ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Radiofrequency Ablation ◽  
Randomized Controlled Trials ◽  
Tumor Progression ◽  
Transcatheter Arterial Chemoembolization ◽  
Meta Analysis ◽  
Cochrane Library ◽  
Controlled Trials ◽  
Randomized Controlled ◽  
Arterial Chemoembolization

Abstract Background To evaluate the curative effect and safety of compare radiofrequency ablation (RFA) with or without transcatheter arterial chemoembolization (TACE) in the treatment of hepatocellular carcinoma (HCC)with the help of a meta-analysis of randomized controlled trials (RCTs) . Materials and Methods RCTs comparing TACE combined with RFA and RFA alone were searched electronically using PubMed, The Cochrane Library, and EMBASE. Fixed and random-effects were used to measure pooled estimates. Research indicators included overall survival (OS), recurrence-free survival (RFA), tumor progression and complications. Results Overall, 6 RCTs were included in this meta-analysis, with a total of 527 patients (TACE-RFA: 271; RFA: 256). 3- and5-year OS rate was higher in the TACE-RFA group than in the RFA group (OR = 1.74; 95% CI: 1.17–2.59; p = 0.006; OR = 2.19; 95% CI: 1.49–3.22; p < 0.0001). The 3- and 5-year RFS rate in the TACE-RFA group was higher than that in the RFA group (OR = 1.92, 95% CI: 1.30 ~ 2.82, p = 0.0009; OR = 1.81, 95% CI: 1.21 ~ 2.70, p = 0.004, respectively). The rate of tumor progression was lower in the TACE-RFA group than in the RFA group (OR = 0.57; 95% CI: 0.38 ~ 0.85; p = 0.005). No significant differences in terms of 1-year OS rate and complications rate were observed between groups.

Sign in / Sign up

Export Citation Format

Share Document